Acadian Asset Management LLC Salarius Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$0.8 - $1.15 $17,392 - $25,002	-21,741 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$1.02 - $1.52 $22,175 - $33,046	21,741 New	21,741 $23,000
Q2 2020 Aug 12, 2020	SELL	$0.6 - $1.82 $5,137 - $15,584	-8,563 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$3.02 - $5.9 $28,297 - $55,283	-9,370 Reduced 52.25%	8,563 $32,000
Q3 2019 Nov 07, 2019	BUY	$5.28 - $20.25 $94,686 - $363,143	17,933 New	17,933 $97,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.